Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) said hat Ortho-McNeil Pharmaceutical, Inc. exercised its option to extend the research term for one additional year under the provisions of its partnership with Arena to develop compounds targeting the Glucose-Dependent Insulinotropic Receptor, or GDIR.


Comments